This article is for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) - including midgut carcinoid, pancreatic NETs, and related tumor types. PRRT stands for peptide receptor radionuclide therapy. The drug discussed here is lutetium Lu-177 dotatate, sold under the brand name Lutathera. If you are looking for information about Lu-177 therapy for prostate cancer, that is a separate clinical track not covered in this article.
If you live in Saudi Arabia or elsewhere in the Gulf Cooperative Council (GCC) region and you have a somatostatin receptor-positive neuroendocrine tumor, you may have been told that PRRT is not available near you. That experience is common across the region. This article explains the access gap, what PRRT in India looks like, what it costs compared to the United States, and what steps Saudi patients typically take to reach treatment.
Is PRRT Available in Saudi Arabia?
Delivering PRRT safely requires specialized infrastructure. A center needs a licensed nuclear medicine department, a reliable supply chain for lutetium-177, a hospital radiopharmacy to prepare each patient-specific dose, shielded post-infusion monitoring rooms, and an experienced multidisciplinary team in NET care. These requirements mean that PRRT is found in only a small number of centers globally - mostly in Western Europe, North America, Australia, and India.
As of 2025, dedicated PRRT programs in Saudi Arabia and the broader GCC region remain limited. Doctors at major referral hospitals in Riyadh or Jeddah often recommend that patients seek this treatment abroad. Many patients won't wait for local infrastructure to grow while their tumor progresses. That is why a growing number of Saudi patients travel to India for PRRT. India has offered PRRT for over a decade, and several large accredited cancer centers now run established, high-volume lutetium therapy programs with English-speaking international patient teams.
How Does the Cost of PRRT Compare: India, the United States, and the GCC?
| Factor | India | United States | Saudi Arabia / GCC |
|---|---|---|---|
| Approx. cost per cycle | USD 5,000-9,000 (2024-2025, varies by center) | Approx. USD 55,896 per dose at list price (WAC, 2026) | Not routinely available locally; request a written quote if referred abroad |
| Approx. full course (4 cycles) | USD 20,000-36,000 total | Approx. USD 220,000+ at list price (4 doses) | Costs depend on the country of referral |
| Typical wait for first cycle | 2-6 weeks after eligibility is confirmed | Variable; insurance pre-authorization may take weeks to months | Referral abroad typically required; timeline depends on the referral pathway |
| Eligibility scan required | Ga-68 DOTATATE PET-CT; can often be arranged in India on arrival | Ga-68 DOTATATE PET-CT or equivalent somatostatin receptor imaging | Ga-68 DOTATATE PET-CT; availability in GCC is limited at some centers |
| Language and coordination | English-speaking care teams; international patient coordinators widely available | English; complex insurance navigation for non-US patients | Arabic and English widely spoken; coordination depends on the referral center |
India per-cycle cost range sourced from hospital pricing data published by Gleneagles Hospitals (2024-2025). US list price (wholesale acquisition cost, 2026) sourced from the Healthline Lutathera Cost Guide (2026). Actual costs at any facility may differ; always request a written quote before committing to travel.
The cost difference between India and the United States is large. A full four-cycle PRRT course in India may cost between USD 20,000 and USD 36,000 at established centers. The same course in the US costs more than USD 220,000 based on published wholesale acquisition costs of approximately USD 55,896 per dose. For Saudi patients without insurance coverage for international treatment, India is often the most affordable path to PRRT available today. For a fuller country-by-country breakdown that also covers UK and UAE pricing, see our guide to PRRT costs in India versus the US, UK, and UAE.
Who Is Eligible for Lu-177 DOTATATE?
The first step in finding out whether PRRT is right for you is a Ga-68 DOTATATE PET-CT scan. This imaging test reveals whether your tumor cells express somatostatin receptors at a level high enough for lutetium Lu-177 dotatate to bind to them. The Neuroendocrine Tumor Research Foundation explains that adequate uptake on this scan is the key factor for PRRT eligibility. If receptor expression is low, the treatment is unlikely to reach your tumor cells effectively.
Other factors your care team will assess include:
- Tumor differentiation and grade: lutetium Lu-177 dotatate is generally used for well-differentiated grade 1 or grade 2 NETs
- Kidney function: the kidneys filter lutetium from the body, so baseline kidney health must be adequate before each cycle
- Bone marrow reserve: blood counts are checked to confirm you can tolerate the therapy
- Overall performance status: most patients need to be reasonably mobile and not in acute medical crisis
- Prior treatment history: having received somatostatin analogues such as octreotide or lanreotide does not usually disqualify you from PRRT
The US Food and Drug Administration approved lutetium Lu-177 dotatate for somatostatin receptor-positive GEP-NETs in January 2018. That approval was based on the phase 3 NETTER-1 trial, which showed that PRRT offered significantly longer progression-free survival compared to high-dose octreotide alone - a hazard ratio of 0.18, meaning the PRRT group had markedly lower risk of disease progression. The full NETTER-1 results are published via PubMed Central for those who want to read the primary evidence.
If your NET has spread to the liver, eligibility depends on how much of the liver is involved and how well it functions. Liver metastases do not automatically rule out PRRT. Our guide to Lu-177 DOTATATE eligibility when your NET has spread to the liver covers this question in detail.
What Does the PRRT Journey Look Like from Saudi Arabia?
For most Saudi patients, the path to PRRT in India follows a clear, manageable sequence.
- Gather your medical records. Collect your pathology report with tumor grade and Ki-67 index, all prior imaging on disc or digital format, your somatostatin receptor scan if you have had one, recent blood results, your current medication list, and your oncologist's most recent treatment notes. Having these in English will speed up the review process considerably.
- Request a remote eligibility review before booking travel. Share your records with a PRRT-experienced team by email or through a secure patient portal. A remote review can give you a clear picture of whether you are likely to qualify and what additional tests you may need. This step prevents unnecessary trips and helps you set realistic expectations before you travel.
- Arrange your Ga-68 DOTATATE PET-CT if you have not had one yet. If a Ga-68 DOTATATE PET-CT has not been done in Saudi Arabia, it can usually be scheduled in India as part of your first-visit workup. You don't need this scan before you travel, though having it done earlier can shorten the time between your arrival and starting treatment.
- Plan your travel for the first cycle. Most patients stay in India for 3 to 5 days per cycle. The lutetium infusion itself takes several hours. After the infusion, you'll stay in a shielded room for approximately 24 hours for radiation monitoring before discharge. Cycles are then spaced 6 to 8 weeks apart.
- Decide whether to return home between cycles. Many GCC patients fly back to Saudi Arabia after each cycle and return to India for the next one. Others arrange a longer stay if they prefer not to travel repeatedly. Your care team in India will give you written guidelines on when flying is safe after receiving lutetium. Most patients can travel commercially within a few days of discharge, following standard radiation-precaution instructions.
- Continue follow-up monitoring between cycles. Doctors perform blood tests before each cycle. Doctors usually order restaging imaging after two or three cycles. Your India-based team can share results with your oncologist at home so coordination continues between your teams.
For a closer look at exactly what the first appointment involves - what scans are ordered, what questions the team will ask, and what to bring - see our article on what to expect at your first PRRT consultation in India.
Confirming Eligibility Before You Travel
Traveling to another country for cancer treatment is a real commitment of time, money, and energy. You want to know before you board a flight whether PRRT is actually appropriate for your specific case, what the realistic picture looks like, and what happens if PRRT isn't right for you. Getting that clarity remotely, before any booking, is the most important step you can take. You can arrange a teleconsultation with the Art of Healing Cancer team, whose nuclear medicine specialists regularly review NET cases from GCC patients. They can assess your pathology and imaging and give you an honest answer on suitability - including alternatives available if lutetium Lu-177 dotatate is not right for your situation.
What to Expect During Treatment and How to Support Your Body
Each PRRT infusion takes several hours. Doctors give amino acid solutions before and during the lutetium infusion as a standard kidney-protective measure - this reduces the radiation dose absorbed by the kidneys during treatment. After the infusion ends, you'll stay in a shielded hospital room for around 24 hours while radiation levels drop enough for safe discharge.
The most common side effect in the days after each cycle is fatigue. Nausea can occur during or shortly after the infusion and is generally manageable with medication provided by your care team. Most patients describe being able to return to normal daily activities within about a week of each cycle, though individual responses vary. The NETTER-1 trial found that clinically significant bone marrow suppression occurred in fewer than 10 percent of patients receiving lutetium Lu-177 dotatate.
Between cycles, many patients focus on nutrition, adequate rest, and managing symptoms related to the NET itself - such as flushing or diarrhea in carcinoid syndrome. For those looking at over-the-counter options to support general resilience during this period, you can see the evidence-based Immunity and Wellness options at Ayurnomics. Always check with your oncologist or nuclear medicine team before starting any supplement, as some preparations may interact with treatment or affect kidney and liver function tests.
After discharge from each cycle, radiation-safety precautions apply for a short period - typically three to five days. These include limiting prolonged close contact with young children and pregnant women, flushing the toilet twice, and using a separate set of utensils temporarily. Your care team will give you written precaution instructions that are also appropriate for the return flight home.
What If PRRT Is Not the Right Option for My Case?
Not every NET patient will qualify for PRRT. Low somatostatin receptor uptake on the Ga-68 DOTATATE PET-CT scan means lutetium Lu-177 dotatate is unlikely to reach the tumor cells with enough dose to be useful. Doctors generally do not use PRRT for high-grade tumors - grade 3 NETs or neuroendocrine carcinomas. Severely reduced kidney function or very low blood counts can also be limiting factors, though these situations may sometimes be managed with additional support depending on their severity.
If PRRT is not appropriate for your case right now, active treatment options may still exist. Somatostatin analogues, everolimus, sunitinib, and other targeted approaches remain relevant depending on your tumor type, grade, and prior treatment history. A thorough eligibility review should always include an honest discussion of what comes next if lutetium is not a fit. To understand how PRRT fits alongside somatostatin analogue therapy more broadly, our guide on when to consider switching from somatostatin analogues to PRRT may help you frame that conversation with your oncologist.
If you would like a formal case review or want to send your scans and pathology for assessment, you can reach the team through the Lutetium Therapy contact form. If PRRT isn't suitable for your case, the review will cover what alternatives may be worth exploring for your specific NET.
When to talk to your doctor: Speak with your oncologist or a nuclear medicine specialist if your neuroendocrine tumor has progressed despite somatostatin analogues, if an oncologist thinks you may be a candidate for PRRT, if you want to understand whether your Ga-68 DOTATATE PET-CT result makes you eligible, or if you are considering traveling to India for treatment and need help coordinating care between your teams in both countries.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Is PRRT with lutetium Lu-177 dotatate available in Saudi Arabia?
As of 2025, dedicated PRRT programs in Saudi Arabia and the wider GCC region are limited. Most patients who are eligible for PRRT are advised to seek treatment abroad. India is the most common destination for GCC patients because of its established nuclear medicine programs, English-speaking international patient teams, and significantly lower costs compared to the US or Europe. Your oncologist may be able to make a referral, or you can request an independent remote eligibility review to determine whether PRRT is right for your case before deciding where to go.
How many cycles of Lu-177 DOTATATE will I need?
The standard PRRT course involves four cycles, each spaced approximately 6 to 8 weeks apart. This protocol is based on the NETTER-1 trial, which established lutetium Lu-177 dotatate as effective for progressive midgut neuroendocrine tumors. Your care team may adjust the number of cycles based on your individual response to treatment and how well your kidneys and bone marrow are tolerating each cycle.
Do I need a Ga-68 DOTATATE PET scan before traveling to India for PRRT?
A Ga-68 DOTATATE PET-CT scan is required to confirm somatostatin receptor expression before PRRT can be given. If you have already had this scan in Saudi Arabia, the results can usually be reviewed remotely by the India-based team. If you have not had one yet, it can typically be arranged in India as part of your pre-treatment evaluation during your first visit, which means you do not necessarily need to delay travel until you have had the scan at home.
Can I fly home to Saudi Arabia between PRRT cycles in India?
Yes, most GCC patients do fly home between cycles. After each lutetium infusion, a period of radiation precautions applies - typically three to five days. After that window, air travel is generally acceptable. Your care team in India will give you written radiation-safety instructions and guidance on when flying is appropriate. The 6 to 8 week gap between cycles gives patients from Saudi Arabia enough time to return home, recover, and then travel back for the next cycle.
What documents should I bring when traveling to India for a PRRT eligibility review?
Bring your pathology report with tumor grade and Ki-67 index, all relevant imaging on disc or in digital format (including any DOTATATE or octreotide PET-CT), recent blood test results including kidney and liver function, a list of your current medications, and your oncologist's most recent treatment summary. Having these records in English, or with an accurate translation, will allow the team in India to carry out a thorough review more quickly.
What happens if PRRT does not work for my neuroendocrine tumor?
If PRRT does not produce a response, or if you are found not to be eligible after your eligibility review, your NET team will discuss other options. These may include continued or adjusted somatostatin analogue therapy, targeted agents such as everolimus or sunitinib, liver-directed treatments if your disease is mainly in the liver, or clinical trials depending on what is available. A good PRRT eligibility review should always include a frank, honest conversation about what the next step would be if lutetium Lu-177 dotatate is not suitable for your case.